Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,416.00+0.10%ETH$2,442.29+0.95%GOLD$4,397.70-0.05%OIL$100.86-1.03%
Smart Investors Daily
RE

NASDAQ · REUN

Reunion Neuroscience Inc.

Healthcare · Biotechnology

$1.12

Down-$0.01 (-0.88%)

Updated Sep 18, 2026, 2:03 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
13.12M
P/E ratio
-0.34
Dividend yield
0.00%
52-week range
— – —
Volume
19K
Avg. volume
500.06K

Price performance

REUN price history

1M range · 0 trading sessions · Daily adjusted prices

REUN does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest REUN news

The latest Smart Investors Daily articles mentioning REUN.

Stock researchCompany · Overview

REUN research

Overview

Company profile and research snapshot.

Company profile

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
REUN recent ratings
DateFirmRatingTarget
May 1, 2023ThinkEquityBuy—
Feb 15, 2023HC Wainwright & Co.Buy—
Feb 14, 2023EF HuttonBuy—
Dec 16, 2022EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

globenewswire.com · Sep 30, 2025

Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses

-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- -- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 Trial of RE104 in Postpartum Depression (PPD) in 2026 and RECLAIM Phase 2 Trial in Generalized Anxiety Disorder (GAD) in 1Q 2026--

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By